Investigating the role of gut bacteria in Parkinson's disease
A cross-sectional and longitudinal study of gut microbiota in Parkinson's disease
This study is looking at how the bacteria in your gut might affect Parkinson's disease, and it aims to find specific types of gut bacteria that could help track the disease's progress, so if you have Parkinson's, your participation could help improve understanding of your condition.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10987823 on NIH RePORTER |
What this research studies
This research explores how changes in gut microbiota may influence the development and progression of Parkinson's disease (PD). By examining fecal samples and clinical data from PD patients, the study aims to identify specific gut bacteria that could serve as biomarkers for the disease. The research will involve both cross-sectional and longitudinal approaches, allowing for a comprehensive understanding of gut health in relation to PD symptoms. Patients will be monitored over time to assess how gut microbiota changes correlate with their clinical condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Parkinson's disease, particularly those experiencing gastrointestinal symptoms like constipation.
Not a fit: Patients without a diagnosis of Parkinson's disease or those who do not experience gastrointestinal issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new microbiome-based treatments that improve the management of Parkinson's disease.
How similar studies have performed: Previous research has shown promising results in understanding the gut-brain connection in various neurological conditions, suggesting potential for success in this novel approach.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Xie, Tao — University of Chicago
- Study coordinator: Xie, Tao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.